Hsbc Holdings PLC Raises Position in REGENXBIO Inc. (NASDAQ:RGNX)

Hsbc Holdings PLC grew its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 37.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,916 shares of the biotechnology company’s stock after purchasing an additional 5,389 shares during the quarter. Hsbc Holdings PLC’s holdings in REGENXBIO were worth $234,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of RGNX. Perceptive Advisors LLC bought a new position in REGENXBIO during the 4th quarter valued at $6,146,000. Virtu Financial LLC bought a new position in REGENXBIO during the fourth quarter valued at $377,000. PNC Financial Services Group Inc. increased its position in REGENXBIO by 73.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after buying an additional 746 shares during the last quarter. Napatree Capital LLC bought a new stake in shares of REGENXBIO in the fourth quarter valued at $720,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of REGENXBIO by 44.2% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 106,284 shares of the biotechnology company’s stock valued at $2,239,000 after buying an additional 32,584 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RGNX. HC Wainwright reissued a “buy” rating and issued a $39.00 price objective on shares of REGENXBIO in a report on Wednesday, September 4th. Barclays lowered their price target on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. The Goldman Sachs Group began coverage on shares of REGENXBIO in a report on Friday, June 7th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.91.

Insider Activity at REGENXBIO

In other REGENXBIO news, Director Kenneth T. Mills sold 2,210 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $13.77, for a total value of $30,431.70. Following the sale, the director now owns 408,035 shares in the company, valued at approximately $5,618,641.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kenneth T. Mills sold 2,210 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total value of $30,431.70. Following the completion of the sale, the director now directly owns 408,035 shares in the company, valued at approximately $5,618,641.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 65,279 shares of company stock valued at $864,034 in the last three months. Company insiders own 13.13% of the company’s stock.

REGENXBIO Trading Up 4.0 %

Shares of NASDAQ RGNX opened at $9.72 on Friday. The firm has a fifty day simple moving average of $11.94 and a two-hundred day simple moving average of $14.21. REGENXBIO Inc. has a 12 month low of $9.29 and a 12 month high of $28.80. The firm has a market capitalization of $480.36 million, a PE ratio of -1.65 and a beta of 1.22.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.24. The business had revenue of $22.30 million during the quarter, compared to analyst estimates of $22.97 million. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.66) earnings per share. On average, sell-side analysts predict that REGENXBIO Inc. will post -4.66 earnings per share for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.